Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Trump threatens to bomb Oman over Iran stance
Progenics' (PGNX) Relistor Setback Only a Speedbump - Jefferies
April 5, 2016 9:34 AM EDTJefferies analyst, Gena Wang, sees the FDA extension for Progenics Pharmaceuticals' (NASDAQ: PGNX) oral Relistor as a timing setback only. No change to Buy rating or $9 PT.
The FDA extended the PDUFA by 3mon (to July 19) for oral Relistor in opioidinduced constipation in... More
Valeant Pharma (VRX), Progenics (PGNX) PDUFA for Oral RELISTOR Extended by 3 Months
April 4, 2016 7:03 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Oral... More
